Future studies, however, are required to explore possible mechanisms unrelated to the mTORC1/Mcl-1 pathway, such as inhibition of Bad or enhancement of CXCR4 signaling [16], through which Pim kinases may mediate to confer therapy resistance on FLT3-ITD-driven AML cells. This evidence concerns the gene BAD and acute myeloid leukemia.